The Filing Desk

Relay Therapeutics

RLAY · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

RLAY · Last close · November 13, 2026
$18.09
Value Relay Therapeutics yourself

Relay Therapeutics' revenue rose 53.4% to $15 million in fiscal 2025. Its operating margin was −1,971.6%, up from −3,722.1% a year earlier. Free cash flow was −$236 million. The diluted share count rose 20.1%.

RELAY THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076739 Updated
Revenue
$15M
53.4%
Operating margin
−1,971.6%
1750.5 pts
Net income
−$276M
 
Free cash flow
−$236M
 
Return on equity
−41.1%
3.0 pts
Market cap
$4.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Relay Therapeutics does

Relay Therapeutics is a clinical-stage drug developer. It has no approved products and no product sales. It develops small-molecule medicines, meaning drugs in pill form, for cancer and for genetic diseases.

Its approach rests on a platform it calls Dynamo, which combines computer modeling and lab experiments to study how proteins move. The company says this helps it design drugs for protein targets that were hard or impossible to hit with older methods. It chooses targets where there is clear evidence linking a protein to a disease and where a diagnostic test can identify the patients who would benefit.

Its lead candidate is zovegalisib, also called RLY-2608. It is an inhibitor of a protein called PI3K alpha, and the company describes it as the first of its kind to block only certain mutated forms of the protein. Its main trial is in breast cancer and other solid tumors, where it is being tested with the drug fulvestrant and, in a three-drug combination, with a drug candidate from Pfizer. Relay pays for its research with money it raises and with deals with partners. It had 192 full-time employees at the end of 2025.

Its biggest risks, as it describes them

  • It has never completed a large pivotal clinical trial, and its drug candidates may fail in trials.
  • Its drugs use a new approach, which may bring added costs, regulatory hurdles or unexpected side effects.
  • Testing its drugs in combination with other cancer treatments makes side effects harder to predict.
  • Delays in enrolling patients or in getting regulatory approvals could hold up its drug candidates.
  • It faces strong competition, and insurers may not cover or reimburse its drugs if approved.
From Relay Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Relay Therapeutics lost money in fiscal 2025: a net loss of $276 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments28015214412484
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio40.1x16.0x25.4x15.9x22.6x
Quick ratio40.1x16.0x25.4x15.9x22.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Relay Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Relay Therapeutics shares on the open market, and 5 insiders sold $127.9 million, $10.6 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 8, 2026Sanjiv PatelPresident and CEO, DirectorSold plan48,199$18.94$912,889Form 4
Sep 8, 2026Thomas CatinazzoChief Financial OfficerSold plan17,717$18.94$335,560Form 4
Sep 8, 2026Donald A BergstromPresident, R&DSold plan8,530$18.97$161,814Form 4
Aug 26, 2026Peter RahmerSee remarksSold plan4,508$20.03$90,295Form 4
Aug 25, 2026Sb Investment Advisers (uk) Ltd10% ownerSold6,000,000$19.40$116.4 millionForm 4
Aug 17, 2026Sanjiv PatelPresident and CEO, DirectorSold plan48,199$20.33$979,886Form 4
Aug 14, 2026Thomas CatinazzoChief Financial OfficerSold plan17,717$19.74$349,734Form 4
Jul 28, 2026Donald A BergstromPresident, R&DSold2,237$18.61$41,631Form 4
Jul 28, 2026Thomas CatinazzoChief Financial OfficerSold1,459$18.61$27,152Form 4
Jul 28, 2026Peter RahmerSee remarksSold748$18.61$13,920Form 4
Jul 7, 2026Sanjiv PatelPresident and CEO, DirectorSold plan48,199$19.58$943,736Form 4
Jul 6, 2026Thomas CatinazzoChief Financial OfficerSold plan17,717$18.69$331,131Form 4
The latest 12 of 30 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40558.1%−2,570.3%−1,482.6%
Altman Z''5.965.072.96
Accruals ratio−4.3%−10.3%−5.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Relay Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Relay TherapeuticsFY2553.4%−1,971.6%−1,536.1%———
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3Compare
Janux TherapeuticsFY25−5.5%−1,576.7%−832.8%———Compare
Taysha Gene TherapiesFY2517.3%−1,130.7%−960.1%——4Compare
Roivant SciencesFY25−71.6%−6,235.7%−9,183.5%−62.6%—1Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—8331261015
Revenue growth——−96.3%−54.4%1,749.8%−60.8%53.4%
Gross profit———————
Research and development70100173246330319261
Operating income−84−56−365−299−373−372−303
Net income−75−52−364−290−342−338−276
Diluted EPS (US$)−21.82−5.40−3.82−2.59−2.79−2.36−1.61
Diluted shares (millions)44395112123143172
Cash flow
Cash from operations−66−102−74−230−300−249−236
Capital expenditure8249420
Free cash flow−74−104−78−239−304−251−236
Dividends paid0000000
Share buybacks0000000
Acquisitions00250000
Stock-based compensation4324856869462
Balance sheet at fiscal year end
Cash and short-term investments4244828015214412484
Debt incl. finance leases———————
Total assets3938001,0081,100844871621
Total liabilities3636111150929454
Shareholders' equity−180763898950752778567
Margins and ratios
Gross margin———————
Operating margin—−67.5%−12,040.2%−21,670.9%−1,460.1%−3,722.1%−1,971.6%
Net margin—−63.4%−12,012.9%−21,036.1%−1,338.7%−3,374.7%−1,800.6%
Free cash flow margin—−126.3%−2,571.1%−17,273.9%−1,191.7%−2,509.5%−1,536.1%
Rule of 40 (growth + FCF margin)——−2,667.4%−17,328.3%558.1%−2,570.3%−1,482.6%
Return on capital———————
Return on equity—−18.0%−43.8%−31.4%−40.2%−44.1%−41.1%
Return on assets—−8.8%−40.2%−27.6%−35.2%−39.4%−37.0%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Relay Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Relay Therapeutics.